Dosage of Dyrk1a shifts cells within a p21-Cyclin D1 signaling map to control the decision to enter the cell cycle

Molecular Cell

Volumn 52, Issue 1, 2013, Pages 87-100

  Chen, Jia Yun ^a   Lin, Jia Ren ^a   Tsai, Feng Chiao ^a   Meyer, Tobias ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; PROTEIN P21;

ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL FATE; CELL PROLIFERATION; CHROMOSOME 21; DOWN SYNDROME; DYRK1A GENE; FIBROBLAST; GENE; GENE ACTIVITY; GENE CONTROL; GENE DOSAGE; GENE EXPRESSION; GENE LOSS; HUMAN; HUMAN CELL; MAMMAL CELL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SINGLE CELL ANALYSIS;

CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRACKING; CHROMOSOMES, HUMAN, PAIR 21; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOWN SYNDROME; FIBROBLASTS; G1 PHASE; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICROSCOPY, FLUORESCENCE; MICROSCOPY, VIDEO; PHOSPHORYLATION; PROTEIN STABILITY; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; RAS PROTEINS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TIME-LAPSE IMAGING; TRANSFECTION;

EID: 84885334501     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2013.09.009     Document Type: Article

References (33)

1. Altafaj X., Dierssen M., Baamonde C., Martí E., Visa J., Guimerà J., Oset M., González J.R., Flórez J., Fillat C., Estivill X. Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome. Hum. Mol. Genet. 2001, 10:1915-1923.
2. Becker W. Emerging role of DYRK family protein kinases as regulators of protein stability in cell cycle control. Cell Cycle 2012, 11:3389-3394.
3. Becker L., Mito T., Takashima S., Onodera K. Growth and development of the brain in Down syndrome. Prog. Clin. Biol. Res. 1991, 373:133-152.
4. Bornstein G., Bloom J., Sitry-Shevah D., Nakayama K., Pagano M., Hershko A. Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase. J.Biol. Chem. 2003, 278:25752-25757.
5. Burton D.G., Sheerin A.N., Ostler E.L., Smith K., Giles P.J., Lowe J., Rhys-Williams W., Kipling D.G., Faragher R.G. Cyclin D1 overexpression permits the reproducible detection of senescent human vascular smooth muscle cells. Ann. N Y Acad. Sci. 2007, 1119:20-31.
6. Chen J.Y., Lin J.R., Cimprich K.A., Meyer T. A two-dimensional ERK-AKT signaling code for an NGF-triggered cell-fate decision. Mol. Cell 2012, 45:196-209.
7. Coleman M.L., Marshall C.J., Olson M.F. Ras promotes p21(Waf1/Cip1) protein stability via a cyclin D1-imposed block in proteasome-mediated degradation. EMBO J. 2003, 22:2036-2046.
8. Contestabile A., Fila T., Ceccarelli C., Bonasoni P., Bonapace L., Santini D., Bartesaghi R., Ciani E. Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with Down syndrome and in Ts65Dn mice. Hippocampus 2007, 17:665-678.
9. Coyle J.T., Oster-Granite M.L., Reeves R.H., Gearhart J.D. Down syndrome, Alzheimer's disease and the trisomy 16 mouse. Trends Neurosci. 1988, 11:390-394.
10. Demidenko Z.N., Blagosklonny M.V. Growth stimulation leads to cellular senescence when the cell cycle is blocked. Cell Cycle 2008, 7:3355-3361.
11. Diehl J.A., Zindy F., Sherr C.J. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev. 1997, 11:957-972.
12. Fotaki V., Dierssen M., Alcántara S., Martínez S., Martí E., Casas C., Visa J., Soriano E., Estivill X., Arbonés M.L. Dyrk1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice. Mol. Cell. Biol. 2002, 22:6636-6647.
13. Hasle H., Clemmensen I.H., Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000, 355:165-169.
14. Hengst L., Göpfert U., Lashuel H.A., Reed S.I. Complete inhibition of Cdk/cyclin by one molecule of p21(Cip1). Genes Dev. 1998, 12:3882-3888.
15. Hewitt C.A., Ling K.H., Merson T.D., Simpson K.M., Ritchie M.E., King S.L., Pritchard M.A., Smyth G.K., Thomas T., Scott H.S., Voss A.K. Gene network disruptions and neurogenesis defects in the adult Ts1Cje mouse model of Down syndrome. PLoS ONE 2010, 5:e11561.
16. Himpel S., Panzer P., Eirmbter K., Czajkowska H., Sayed M., Packman L.C., Blundell T., Kentrup H., Grötzinger J., Joost H.G., Becker W. Identification of the autophosphorylation sites and characterization of their effects in the protein kinase DYRK1A. Biochem. J. 2001, 359:497-505.
17. Jimenez-Sanchez G., Childs B., Valle D. Human disease genes. Nature 2001, 409:853-855.
18. Kimura M., Cao X., Skurnick J., Cody M., Soteropoulos P., Aviv A. Proliferation dynamics in cultured skin fibroblasts from Down syndrome subjects. Free Radic. Biol. Med. 2005, 39:374-380.
19. Litovchick L., Florens L.A., Swanson S.K., Washburn M.P., DeCaprio J.A. DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly. Genes Dev. 2011, 25:801-813.
20. Massagué J. G1 cell-cycle control and cancer. Nature 2004, 432:298-306.
21. Niepel M., Spencer S.L., Sorger P.K. Non-genetic cell-to-cell variability and the consequences for pharmacology. Curr. Opin. Chem. Biol. 2009, 13:556-561.
22. Park J., Song W.J., Chung K.C. Function and regulation of Dyrk1A: towards understanding Down syndrome. Cell. Mol. Life Sci. 2009, 66:3235-3240.
23. Ren S., Rollins B.J. Cyclin C/cdk3 promotes Rb-dependent G0 exit. Cell 2004, 117:239-251.
24. Sakaue-Sawano A., Kurokawa H., Morimura T., Hanyu A., Hama H., Osawa H., Kashiwagi S., Fukami K., Miyata T., Miyoshi H., et al. Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. Cell 2008, 132:487-498.
25. Salmeen A., Park B.O., Meyer T. The NADPH oxidases NOX4 and DUOX2 regulate cell cycle entry via a p53-dependent pathway. Oncogene 2010, 29:4473-4484.
26. Segal D.J., McCoy E.E. Studies on Down's syndrome in tissue culture. I. Growth rates and protein contents of fibroblast cultures. J.Cell. Physiol. 1974, 83:85-90.
27. Serrano M., Lin A.W., McCurrach M.E., Beach D., Lowe S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997, 88:593-602.
28. Sherr C.J. Cancer cell cycles. Science 1996, 274:1672-1677.
29. Sherr C.J., Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999, 13:1501-1512.
30. Takahashi-Yanaga F., Mori J., Matsuzaki E., Watanabe Y., Hirata M., Miwa Y., Morimoto S., Sasaguri T. Involvement of GSK-3beta and DYRK1B in differentiation-inducing factor-3-induced phosphorylation of cyclin D1 in HeLa cells. J.Biol. Chem. 2006, 281:38489-38497.
31. Ullmannová V., Stöckbauer P., Hradcová M., Soucek J., Haskovec C. Relationship between cyclin D1 and p21(Waf1/Cip1) during differentiation of human myeloid leukemia cell lines. Leuk. Res. 2003, 27:1115-1123.
32. Yan G.Z., Ziff E.B. NGF regulates the PC12 cell cycle machinery through specific inhibition of the Cdk kinases and induction of cyclin D1. J.Neurosci. 1995, 15:6200-6212.
33. Yang Q., Rasmussen S.A., Friedman J.M. Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet 2002, 359:1019-1025.